The Hair Growth Encyclopedia

Dihydrotestosterone (DHT), a byproduct of testosterone created via the enzyme 5-alpha reductase, binds androgen receptors in genetically susceptible scalp follicles roughly five times more strongly than testosterone itself. Over repeated cycles, this progressively shortens the anagen (growth) phase and shrinks — 'miniaturizes' — follicles, producing shorter, finer hairs and eventually no visible hair at all.

There are multiple forms of the 5-alpha reductase enzyme, commonly referred to as type I and type II, and they're distributed differently across the body. Type II activity is concentrated in hair follicles, the prostate, and other androgen-sensitive tissue, which is part of why finasteride (a selective type II inhibitor) can meaningfully reduce scalp DHT levels while leaving other androgen pathways comparatively less affected. Dutasteride, by contrast, inhibits both type I and type II isoforms, which is one reason it's sometimes discussed as more potent at suppressing DHT, alongside a correspondingly broader side-effect consideration.

It's worth being precise about what 'genetically susceptible' means here: it isn't that people who go bald have more DHT circulating in their bloodstream than people who don't. In most cases, circulating DHT and testosterone levels are unremarkable. What differs is the sensitivity of the androgen receptors in scalp follicles themselves — an inherited trait — which is why hair loss runs in families and why two men with identical hormone panels can have completely different outcomes for their hairline.

DHT drives pattern hair loss in both sexes, which is why it's called androgenetic alopecia in men and women alike — though women generally have lower circulating DHT levels, and hair loss in women often involves additional hormonal and genetic factors, part of why female pattern hair loss tends to present as diffuse thinning rather than the frontal recession typical in men. This is also why anti-androgen approaches that work well in men don't automatically transfer to women in the same way, and why female pattern hair loss often gets evaluated alongside other possible contributors — thyroid function, iron status, and postpartum or perimenopausal hormonal shifts — rather than assumed to be DHT-driven by default.

Every hair follicle on the scalp cycles independently through distinct phases, and understanding this cycle is essential to understanding both why hair loss happens gradually and why treatments take months to show results. The anagen phase is the active growth stage, during which the follicle is producing hair continuously; in a healthy scalp, this phase lasts years for any individual follicle. The catagen phase is a brief transitional stage where growth stops and the follicle begins to shrink. The telogen phase is a resting stage where the hair is no longer growing but hasn't yet been shed, followed by exogen, the shedding phase itself, when the old hair releases and a new anagen cycle can begin underneath it.

In androgenetic alopecia, DHT's effect on genetically susceptible follicles is to progressively shorten the anagen phase with each successive cycle while lengthening the resting telogen phase. Each cycle, the follicle produces a slightly finer, shorter, less pigmented hair than the one before — this is the miniaturization process in action, visible over time as thick terminal hairs are gradually replaced by fine, short vellus-like hairs that provide little to no visible coverage.

Because the cycle unfolds over years rather than days, the practical implication is significant: any topical or oral treatment that acts on this cycle needs enough time to influence at least one, and ideally several, full cycles before its effect becomes visible at the scalp surface. This is the single biggest source of frustration and premature treatment abandonment — people expect a linear, weekly improvement, when the biology is inherently slow and cyclical.

Follicle miniaturization in androgenetic alopecia is only partially reversible, and reversibility declines the longer a follicle has been dormant or miniaturized. Follicles that retain their connection to the arrector pili muscle tend to respond better to treatment; once that structural connection is lost at later stages, regrowth becomes far less likely, and existing bald areas typically require surgical transplantation rather than medical treatment to restore visible density.

It helps to think of reversibility as existing on a spectrum rather than a binary. Early-stage thinning — where follicles are miniaturized but still active and producing visibly finer hair — has the best response to medical intervention, because there's still living, cycling tissue for minoxidil or finasteride to act on. Mid-stage thinning, where an area has visibly thinned but isn't yet fully bald, can sometimes be stabilized or partially thickened, though results are more modest and variable. Fully bald, shiny scalp with no visible fine hair generally indicates follicles that are dormant or lost entirely, and medical treatment at that stage functions mainly to protect the hair that remains elsewhere rather than to regrow what's already gone.

This is also why dermatologists consistently emphasize starting treatment early rather than waiting to 'see how bad it gets first.' The biological window for a strong response narrows over time, not because treatments stop working chemically, but because there are fewer viable follicles left for them to act on. Someone who starts minoxidil or finasteride at the first sign of thinning is working with a very different biological substrate than someone who starts after a decade of untreated progression.

None of this means later-stage hair loss is untreatable — it means the toolbox shifts. For advanced miniaturization or fully bald areas, surgical hair transplantation (relocating follicles that are resistant to DHT, typically from the back and sides of the scalp, to thinning or bald areas) is the standard approach, often combined with ongoing medical treatment to protect both the transplanted and the surrounding native hair from further DHT-driven loss.

Across minoxidil and finasteride, dermatology sources consistently describe a 3-6 month minimum before visible improvement, with fuller results — particularly for minoxidil — sometimes taking 9-12 months. Shedding often temporarily increases in the first weeks of starting minoxidil as the hair cycle resets; this is expected, not a sign of failure.

Breaking that window down further: the first one to two months are typically the least eventful visually, even though the treatment is already acting on the follicle at a cellular level — this is the period during which the initial shedding phase, if it occurs, tends to happen. Months three through six are when most users who are going to respond start to notice a difference, usually first as reduced shedding and a sense that thinning has stopped progressing, before actual density improvement becomes visible. The month nine to twelve mark is generally where results plateau and represent close to the maximum benefit that particular treatment or dose will provide for that individual.

A practical consequence of this timeline is that self-assessment by memory is unreliable — most people don't accurately recall what their hairline or crown looked like six months ago, and normal day-to-day and lighting variation can mask both improvement and continued loss. Taking consistent, well-lit photos from the same angles at the same interval (monthly is common) before starting any treatment, and continuing throughout, is the most reliable way to actually judge whether a treatment is working, rather than relying on impression alone.

It's also worth setting expectations about what 'working' looks like at the ceiling. Medical treatments for androgenetic alopecia are generally better at slowing or stopping further loss and at improving the thickness of existing thinning hair than they are at regrowing hair in areas that have been completely bald for years. A treatment that halts progression and thickens existing fine hair is, by the standards of the condition, a successful outcome — even if it doesn't fully restore a hairline to its appearance a decade earlier.

Before investing months in any treatment, it's worth confirming that what you're experiencing is in fact androgenetic alopecia and not one of several other conditions that can look similar in early stages. Telogen effluvium — a temporary, diffuse shedding triggered by stress, illness, crash dieting, medication changes, or major hormonal shifts (including postpartum) — can resemble the early stages of pattern thinning but typically resolves on its own once the trigger passes, usually without the specific vertex-and-hairline pattern typical of androgenetic alopecia. Alopecia areata, an autoimmune condition, produces distinct patchy bald spots rather than gradual diffuse miniaturization. Thyroid dysfunction, iron deficiency, and certain medications can also cause shedding that mimics pattern hair loss but responds to a completely different intervention.

Dermatologists commonly use standardized visual staging systems — the Norwood-Hamilton scale for men and the Ludwig scale for women — to describe how far pattern hair loss has progressed, from minimal recession at the earliest stages to extensive baldness at the most advanced. These scales are primarily descriptive and communicative tools rather than treatment thresholds, but they're useful for tracking your own progression over time and for having a shared vocabulary when discussing your hair with a dermatologist.

A simple, low-cost way to get a rough read on whether shedding is currently active and abnormal is the 'pull test' — gently pulling a small section of hair (perhaps 50-60 strands) and counting how many come away in your hand — though this is a screening gesture, not a diagnosis, and its result should be interpreted cautiously rather than treated as definitive. If shedding is diffuse, sudden, or accompanied by other symptoms like fatigue, weight changes, or scalp pain or scarring, that's a stronger signal to see a dermatologist for bloodwork and a proper scalp exam before assuming it's garden-variety pattern hair loss and self-treating.

Topical minoxidil and oral or topical finasteride are commonly combined by dermatologists and act through different mechanisms — follicle stimulation versus DHT suppression — without known dangerous interactions between them. Combined use is generally described as more effective than either alone. Each still carries its own distinct side-effect profile: minoxidil's are mostly local scalp irritation, while finasteride's are hormonal (rare sexual side effects, mood changes). Anyone starting a combined regimen, especially with additional supplements or serums layered on top, should do so under a clinician's guidance rather than self-directed stacking of unapproved compounded formulations.

A common mistake is treating 'more products' as inherently 'more effective.' Layering multiple leave-on scalp products — minoxidil, a caffeine or peptide serum, an essential-oil blend, a medicated shampoo used daily instead of a few times a week — increases the odds of cumulative scalp irritation without necessarily adding proportional benefit, and it also makes it much harder to tell which product is responsible if something goes wrong or if something works particularly well. A more disciplined approach is to introduce one new product at a time, give it a full multi-month evaluation window, and only then decide whether to add or swap something else.

Timing and application order also matter more than people expect. Minoxidil needs sufficient contact time with the scalp to absorb properly, so applying other leave-on products immediately before or after it can dilute or displace it before it's had a chance to work. Many dermatologists suggest applying minoxidil first, allowing it to dry fully, before layering anything else on top, and being cautious about combining it with products containing strong actives (retinoids, high-percentage acids) that could compound irritation on an already treatment-exposed scalp.

Finally, combining treatments doesn't mean combining them forever without reassessment. Because both minoxidil and finasteride require ongoing use to maintain their effect — benefits generally reverse within months of stopping — a combined regimen is a long-term commitment, and periodic check-ins with a dermatologist (particularly around any new side effects, medication changes, or life stage changes like planning a pregnancy) are a reasonable part of using either drug responsibly over years rather than months.

The single most common mistake is stopping too early. Because the hair cycle operates on a multi-month timescale, discontinuing a treatment at six or eight weeks — often right around when the temporary shedding phase can occur — means quitting before the treatment ever had a fair chance to demonstrate benefit. Many people who conclude 'it didn't work for me' never actually reached the three-to-six-month mark where most responders start to see results.

A second frequent mistake is inconsistent application. Minoxidil in particular is dose- and frequency-dependent; skipping days, applying too little product, or applying it to damp rather than dry hair (which can dilute the concentration reaching the scalp) all reduce its effective exposure. Consistency matters more than perfection, but consistency has to actually happen for a fair trial.

A third mistake is judging results by feel rather than by photo evidence, which — as covered above — is notoriously unreliable given how gradually both loss and regrowth unfold. And a fourth is assuming that because a treatment worked for someone else, or because a product review online used strong language, it will necessarily work identically for a different person's genetics, stage of loss, and hormonal profile. Response to any hair loss treatment varies meaningfully between individuals, and the honest, evidence-based framing is always in terms of probability and typical range of outcomes, not guarantees.